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Abstract: Recently, aptamers have attracted the attention of many scientists, because they 
not only have all of the advantages of antibodies, but also have unique merits, such as 
thermal stability, low cost, and unlimited applications. In this review, we present the 
reasons why aptamers are known as alternatives to antibodies. Furthermore, several types 
of  in vitro selection processes, including nitrocellulose membrane filtration, affinity 
chromatography, magnetic bead, and capillary electrophoresis-based selection methods, are 
explained in detail. We also introduce various applications of aptamers for the diagnosis  
of diseases and detection of small molecules. Numerous analytical techniques, such as 
electrochemical, colorimetric, optical, and mass-sensitive methods, can be utilized to detect 
targets, due to convenient modifications and the stability of aptamers. Finally, several 
medical and analytical applications of aptamers are presented. In summary, aptamers are 
promising materials for diverse areas, not just as alternatives to antibodies, but as the core 
components of medical and analytical equipment. 
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1. Introduction 
Aptamers are oligonucleotides, such as ribonucleic acid (RNA) and single-strand deoxyribonucleic 
acid (ssDNA) or peptide molecules that can bind to their targets with high affinity and specificity  
due to their specific three-dimensional structures. Especially, RNA and ssDNA aptamers can differ 
from each other in sequence and folding pattern, although they bind to the same target. The concept  
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of joining nucleic acids with proteins began to emerge in the 1980s from research on human 
immunodeficiency virus (HIV) and adenovirus. It indicated that these viruses encode a number of 
small structured RNAs that bind to viral or cellular proteins with high affinity and specificity [1]. In 
the case of HIV, a short RNA ligand called the trans-activation response (TAR) element promotes 
trans-activation and virus replication by binding with the viral Tat protein [2]. The adenovirus also has 
a short RNA aptamer, virus-associated (VA)-RNA, that regulates translation [3,4]. Substantive studies 
on aptamers have progressed since the in vitro selection process called Systematic Evolution of 
Ligands by EXponential enrichment (SELEX) was first reported by both Gold’s group and Szostak’s 
group in 1990 [5,6]. Due to the development of SELEX, which is now a basic technique for the 
isolation of aptamers, many aptamers could be directly selected in vitro against various targets, from 
small biomolecules to proteins and even cells [7]. 
Aptamers have been studied as a bio-material in numerous investigations concerning their use as a 
diagnostic and therapeutic tool and biosensing probe, and in the development of new drugs, drug 
delivery systems, etc. (Figure 1). There have been attempts to search for aptamers that are specific to 
targets involved in various diseases, such as cancer and viral infection. Developed aptamers have been 
studied primarily for applications as diagnostic or therapeutic tools. In 2004, the approval by the Food 
and Drug Administration (FDA) of Macugen, a vascular endothelial growth factor (VEGF)-specific 
aptamer, for the treatment of neovascular (wet) age-related macular degeneration (AMD), is a prominent 
landmark in the application of aptamers [8]. Since then, aptamer technology has been regarded as more 
effective and more authoritative, and the number of studies on the applications of aptamers is rapidly 
increasing. There are many fields to which aptamers may be applied, as outlined below. 
Figure 1. Various application fields of aptamers. 
 
The use of antibodies as the most popular class of molecules for molecular recognition in a wide 
range of applications has been around for more than three decades. Aptamers are widely known as a 
substitute for antibodies, because these molecules overcome the weaknesses of antibodies. The 
advantages of aptamers compared with antibodies are described in the following sections [7]: 
(1) High stability of aptamers: It is well known that proteins are easily denatured and lose their 
tertiary structure at high temperatures, while oligonucleotides are more thermally stable and 
maintain their structures over repeated cycles of denaturation/renaturation. Hence, the greatest 
advantage of oligonucleotide-based aptamers over protein-based antibodies is their stability at Sensors 2012, 12  
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elevated temperatures. Aptamers recover their native conformation and can bind to targets after 
re-annealing, whereas antibodies easily undergo irreversible denaturation [9]. Thus, aptamers 
can be used under a wide range of assay conditions. 
(2)  Production of aptamers (synthesis/modification): The identification and production of 
monoclonal antibodies are laborious and very expensive processes involving screening of a 
large number of colonies. Additionally, the clinical commercial success of antibodies has led to 
the need for very large-scale production in mammalian cell culture [10]. Moreover, 
immunoassays are required to confirm the activity of the antibodies in each new batch, because 
the performance of the same antibody tends to differ depending on the batch. However, 
aptamers, once selected, can be synthesized in quantity with great accuracy and reproducibility 
via chemical reactions. These chemical processes are more cost effective than the production of 
antibodies. Furthermore, aptamers can be easily modified by various chemical reactions to 
increase their stability and nuclease resistance [11,12]. Additionally, it is possible to introduce 
signal moieties, such as fluorophores and quenchers, that greatly facilitate the fabrication of 
biosensors. 
(3) Low immunogenicity of aptamers: Aptamers usually seem to be low-immunogenic and low-toxic 
molecules, because nucleic acids are not typically recognized by the human immune system as 
foreign agents. However, antibodies are significantly immunogenic, which precludes repeat 
dosing [13]. The Eyetech Study Group demonstrated that a VEGF-specific aptamer displayed 
little immunogenicity when given to monkeys in 1,000-fold higher doses [14,15]. 
(4) Variety of target: In instances of toxins or molecules that do not elicit strong immune responses, 
it is difficult to identify and produce antibodies, but aptamers can be generated in sufficient 
numbers. Moreover, aptamers show a high affinity and specificity for some ligands that cannot  
be recognized by antibodies, such as ions or small molecules, indicating that employing aptamers 
as the recognition components may markedly broaden the applications of the corresponding 
biosensors [12]. 
Based on the many advantages described above, aptamers are considered to be an alternative to 
antibodies in many biological applications. 
2. In Vitro Selection 
2.1. General 
As mentioned above, SELEX or in vitro selection is a technique used to isolate aptamers with high 
affinity for a given target from approximately 10
12–10
15 combinatorial oligonucleotide libraries. In 
general, the SELEX process is comprised of three steps that are repeated in order to search for 
nucleotides that are better able to bind to the target (Figure 2) [16]. In the first step (library generation), 
a library, except the initial compound in the library, is converted into single-strand nucleotides that 
consist of random sequence regions, usually 30–40 mers, flanked by the primer binding site. In the 
second step (binding and separation), the target-bound library components are separated from the 
unbound components. This step is generally coupled with several other methods to make selection of 
the target or the library easy and rapid. Finally, in the third step (amplification), the target-bound Sensors 2012, 12  
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library component is amplified by the PCR to create a new library to be used in the next round. 
Aptamers are continuously developed through this on-going process, and their characteristics are 
identified using various biological assays. 
Figure 2. The general SELEX strategy. Starting with combinatorial libraries (first step), 
the specific binders are isolated by an iterative process of ligand binding, elution (second 
step), and amplification (third step). 
 
2.2. Nitrocellulose Membrane Filtration-Based SELEX 
A nitrocellulose membrane is often used to immobilize proteins in Western blots and atomic force 
microscopy (AFM) because it provides simple and rapid protein immobilization by its non-specific 
affinity for amino acids. In 1968, a method using nitrocellulose membranes was employed by Kramlova’s 
group to easily and quickly separate a protein from RNA molecules [17]. This method has been developed 
as a research tool for separating proteins from many other components and for immobilizing proteins, 
which can then react with other biomolecules. When the SELEX method was initially established by 
Gold’s group, the aptamer against the T4 DNA polymerase was obtained using a strategy that was 
based on the use of a nitrocellulose membrane [6]. Because the targets were primarily proteins in the 
early stage of SELEX, the use of a nitrocellulose membrane was applied during the separation step. 
However, these membranes have some limitations, such as being incapable of binding small molecules 
and peptides, and they generally require at least 12 selection rounds [18,19]. 
2.3. Affinity Chromatography and Magnetic Bead-Based SELEX 
Affinity chromatography is a method for separating the components from a biochemical mixture. It 
is primarily used for the purification of recombinant proteins, based on a highly specific biological 
interaction, such as that between a receptor and a ligand, or an antigen and an antibody. The immobile 
phase is generally composed of agarose-based beads, and the beads are packed onto a column for the 
washing and elution processes. In the binding and separation steps of SELEX, affinity chromatography 
assists in the selection of only the library components with an affinity for the target, by immobilizing Sensors 2012, 12  
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target molecules on the beads (Figure 3(a)). In the case of immobilization of proteins, various tags  
such as glutathione S-transferase (GST) and the His-tag are utilized and, in the case of small organic 
molecules, the targets are covalently fixed on the beads via a chemical reaction, such as coupling  
with EDC [20]. Thus, SELEX for small molecules, as well as proteins, can be carried out using this 
method. Several aptamers were selected using this method by making an affinity column containing 
target-immobilized beads [20–22]. However, the disadvantage of this method is that it cannot be 
applied if the target lacks the affinity tag or the functional group needed for coupling to the beads. 
Magnetic beads are also used to immobilize the target via an interaction or a chemical reaction 
between an affinity tag and the substrate on the beads. The use of magnetic beads is an especially 
powerful tool for easy and rapid isolation of target-immobilized beads with a magnet (Figure 3(b,c)). 
Recently, aptamer selection has been involved in linking this magnetic bead-based strategy to   
the SELEX technique. Particularly because the library bound to the target is easily and simply 
separated from the unbound one by a magnet, many attempts at selecting target specific aptamer have 
followed [23–25]. 
Figure 3. (a) A schematic illustration of the selection step from a library using an affinity 
column; (b) The process of the selection step using magnetic beads; (c) Several types of 
functional group-activated beads such as tosyl-activated beads and epoxy-activated beads. 
 
2.4. Capillary Electrophoresis-Based SELEX 
Capillary electrophoresis (CE) possesses several appealing advantages over the other analytical 
separation methods in the aspects of speed, resolution, capacity, and minimal sample dilution. This 
method can separate ionic species by their charge, frictional forces, and hydrodynamic radius under the 
influence of an electric field [18]. With this method, an aptamer can be selected by a mobility shift 
among the mixture of a target, the library, and the target-library complex (Figure 4). In particular, the 
greatest virtue of applying this method to SELEX is that the successful selection of the aptamer can be 
achieved within very few rounds, generally 2–4 rounds, compared to other methods. In Bowser’s group, 
aptamers for neuropeptide Y and human IgE were obtained after only four rounds of selection [26,27]. Sensors 2012, 12  
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Figure 4. Fundamental principle of the selection step using CE. Aptamers are selected 
based on the difference in mobility due to charge and mass. 
 
2.5. Microfluidic-Based SELEX 
In order to select an aptamer more effectively, SELEX using a microfluidic or chip system was 
developed [28]. Since this method is mainly processed on a chip, it is able to enhance selection 
efficiency on a small scale. For example, the DNA aptamer-specific bound to neurotoxin type B was 
obtained after a single round of selection using the Continuous-flow Magnetic Activated Chip-based 
Separation (CMACS) device designed by Soh’s group [29]. Also, the screening of C-reactive protein 
(CRP) specific aptamers was performed automatically utilizing a microfluidic system and magnetic 
beads conjugated with CRP [30]. Microfluidic technology-based SELEX is catching on as an advanced 
method to select aptamers rapidly and automatically. 
2.6. Cell-SELEX 
Cell-SELEX is aimed at searching for an aptamer against a whole cell, whereas the primary targets of 
other SELEX methods are single highly-purified proteins. In other words, the targets of Cell-SELEX  
are extracellular proteins on the cell surface or unique structures of the cell. In the majority of cases, 
Cell-SELEX processes have washing (for adhesive cells) or centrifugation (for suspension cells)   
steps during the separation of aptamers, because target immobilization is not practicable in the solid 
phase. In addition, counter selections are necessary in each round to avoid selection of aptamers that 
non-specifically recognize the cell surface and that are commonly located at the surfaces of many cells. 
Therefore, this method is complicated, because of the impossibility of immobilizing targets, and due to 
counter selection. However, the resulting aptamers, once selected, are powerful for cell-specific 
diagnosis, cell-targeted drug delivery, and cell-specific therapy. 
Recently, in Kobatake’s group, a DNA aptamer for the SBC3, an adherent small cell lung cancer 
(SCLC) cell line, was identified using Cell-SELEX. The aptamer could be a potential SBC3-specific 
marker because this cell line does not express the common biomarker pro-GRP that is used to diagnose 
SCLC [31]. In addition, Tan’s group has selected a series of aptamers that bind to two types of ovarian 
cancer cells: ovarian clear cell adenocarcinomas (TOV-21G) and ovarian serous adenocarcinomas 
(CAOV-3) [32]. In 2003, Gold’s group isolated a GBI-10 aptamer for the U251 cell line, which is 
derived from a human glioblastoma, by performing Cell-SELEX. It was determined that a binding 
partner interacting with the GBI-10 aptamer is the tenascin-C protein on the cell surface [33]. Sensors 2012, 12  
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2.7. Other Method-Based SELEX 
Several methods, such as AFM, electrophoretic mobility shift assays (EMSA), and surface plasmon 
resonance (SPR), have been performed in connection with SELEX [34–37]. Although these strategies 
have the advantage of reducing the number of selection rounds, the effectiveness of these methods in 
selecting the aptamer has not been clearly demonstrated. 
3. Aptamer-Based Sensor 
3.1. General 
A biosensor that is based on aptamers as a recognition element is called an aptasensor [38]. These 
aptasensors can be constructed through a variety of methodologies, including electrochemical biosensors, 
optical biosensors, and mass-sensitive biosensors. 
3.2. Electrochemical Aptasensor 
An electrochemical analysis is an attractive platform, because it offers high sensitivity, compatibility 
with novel microfabrication technologies, inherent miniaturization, and low cost. Therefore, various 
electrochemical aptasensors have been fabricated using several techniques, including EIS, potentiometry 
with ISEs, ECL, CV, and DPV [39–44]. 
To enhance the sensitivity, an AuNRs- or AuNPs-modified conducting polymer was used as a 
material for immobilizing on the electrode [45,46]. Additionally, electroactive reporters, such as 
methylene blue (MB), ferrocence, ferrocence-bearing polymers, ruthenium complexes, and 
Fe(CN)6
4−/3−, are used for signal transduction (Figure 5) [41,47–50]. In Gothelf’s group, a signal-on 
electrochemical aptasensor was designed for theophylline detection using a redox-active Fc moiety, 
which could transfer electrons with the electrode surface by DPV or CV [51]. 
3.3. Fluorescence-Based Optical Aptasensor 
Aptamers have been used as bio-probes in optical sensors based primarily on the incorporation of a 
fluorophore or a nanoparticle. In the case of fluorescence detection, the simplest format is to label the 
aptamers with both a quencher and a fluorophore. A cocaine-specific aptamer-based strategy was able 
to detect the target using a FRET signal between fluorescein and DABCYL moieties (Figure 6(a)) [52]. 
Aptamer beacons are probes that can monitor the presence of the target in solutions using   
fluorophore-quencher pairs. They can change into two or more conformations, such as hairpin shape or 
a hybridization form, by target binding. More complicated formats utilizing quaternary structural 
rearrangements that result in the assembly or disassembly of aptamers were also developed for 
fluorescence signaling (Figure 6(b,c)) [53–55]. Additionally, many nano-materials, including   
QDs, AuNPs, CNTs, graphene oxide (GO), polymer nanobelts, and coordination polymers, have   
been investigated for their fluorescence-quenching effect instead of using a more traditionally 
quencher [56–62]. 
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Figure 5. Examples of electrochemical aptasensors. (a) A schematic representation of the 
electrochemical aptasensor using Fe(CN)6
4−/3−. Part of the aptamer was a hybridized 
aptamer with complementary DNA, which was immobilized on the gold surface. In the 
presence of the target, the aptamer was followed by binding with the target, to decrease the 
amount of the aptamer on the electrode surface; (b) A schematic representation of the 
electrochemical aptasensor using MB. In the presence of the target, the aptamer folds into 
the target-binding three-way junction, altering the electron transfer (eT) and increasing the 
observed reduction peak; (c) A schematic representation of the electrochemical aptasensor 
using Fc. In the presence of the target, the aptamer folds into the restricted hairpin 
structure, and this conformational change results in increased efficiency of eT between the 
Fc probe and the electrode surface. 
 
Figure 6. Schematic illustrations of optical aptasensors using fluorescence. (a) The simplest 
format of a quenching aptamer beacon. The binding of the target stabilizes the stem and 
brings the quencher and fluorophore in close proximity, resulting in fluorescence decrease; 
(b) Assembly aptamer beacon. The binding of the target brings the oligomers together and 
leads to ternary complex stabilization; (c) Disassembly aptamer beacon. The target binding 
induces an antisense displacement and results in a fluorescence increase. 
 Sensors 2012, 12  
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3.4. Colorimetric-Based Optical Aptasensor 
AuNPs or several polymers that cause color changes, can be applied as novel reagents for the optical 
detection technique called colorimetry. The highly negatively-charged ssDNA (complementary strand 
of the aptamer), which is separated from the aptamer by interaction between the aptamer and the 
target, is stabilized against aggregation, and a color change occurs in conjunction with this 
phenomenon (Figure 7(a)) [63]. In contrast to this method, the AuNP disaggregation method was 
employed to detect ATP, cocaine, Pb
2+, and K
+ (Figure 7(b)) [64,65]. After hybridizing under the two 
kinds of oligonucleotides, the aptamer and a linker, the cross-linked AuNPs are released, because the 
aptamer undergoes a conformational change in the presence of the target. These colorimetric strategies 
have the virtue of being easily visible to the naked eye without the need for complicated instruments. 
Figure 7. Schematic illustrations of optical aptasensors using AuNPs. (a) Aptamer release 
and AuNP aggregation by target binding; (b) Aptamer release and AuNP disaggregation by 
target binding. 
 
3.5. Other Aptasensors 
Numerous other aptasensors have been exploited in combination with various types of analytical 
equipment, such as those used for SPR, surface acoustic wave (SAW), QCM, and microchannel 
cantilever sensors (Figure 8) [66–72]. A nanoaptasensor using a single wall nanotube (SWNTs) device 
was developed for detecting small molecules [73]. These methods generally do not require target 
labeling; they only observe the differential changes in optical properties and mass. Therefore, these 
methods are primarily appropriate for relatively large molecules but not for small molecules, including 
organic molecules, toxins, and metabolites [74,75]. Sensors 2012, 12  
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Figure 8. (a) SPR-based aptasensor and (b) microchannel cantilever-based aptasensor. 
 
 
ELISA, one of the major clinical diagnostic tests available, is a versatile technique to detect almost 
any protein or peptide with high sensitivity. One version of ELISA, commonly referred to as sandwich 
ELISA, involves the simultaneous use of two antibodies or analyte-binding receptor proteins to capture 
the analyte or target and to report the target detection (Figure 9(a)). An aptamer-linked immobilized 
sorbent assay (ALISA) was introduced by Kiel’s group. They demonstrated the feasibility of this 
method via a comparative study with ELISA using an antibody (Figure 9(b)). It is important to note 
that aptamers have an unlimited potential to circumvent the limitations associated with antibodies [76]. 
Figure 9. Schematic illustrations of (a) the ELISA method; and (b) the ALISA method. 
 
 
In addition to ELISA, another common tool for clinical diagnosis is RDT, which is a rapid and 
simple method for point-of-care testing (POCT). RDTs for the diagnosis of infectious diseases, such as 
malaria and influenza, are already in use as commercially available tests. Because of the high sensitivity 
of the aptamer, several aptamer-based RDT methods, for many biomarkers related to diseases, have been 
introduced for use in early diagnosis or convenient POCT. In particular, Liu’s group has developed a  
dry-reagent strip biosensor based on aptamers and functionalized AuNPs for use in thrombin analysis 
(Figure 10). In this study, the sensor is subject to visual detection of protein within minutes, with 
sensitivity and specificity that are superior to those of the antibody-based strip sensor [77]. The target 
interacts with the AuNP-primary aptamer conjugate, while the sample solution containing the target Sensors 2012, 12  
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migrates onto each pad. Then, the target-aptamer-AuNP complexes are captured by the secondary 
aptamer that is immobilized in the test zone. Finally, a red band can be observed on the test zone due 
to the accumulation of AuNPs. 
Figure 10. A schematic illustration of an AuNPs-based strip assay. 
 
4.2. Therapy (New Drugs) 
As mentioned above, Macugen, developed by Pfizer and Eyetech, is already commercially available 
for AMD. This drug is a pegylated aptamer, a single strand of nucleic acid with specificity to VEGF165, 
which plays a critical role in angiogenesis and permeability [78]. Additionally, Regado Bioscience has 
developed REG1 as a new aptamer drug for anticoagulation, and this aptamer drug is currently in 
Phase II clinical trials. REG1 consists of two components: RB006 (coagulation factor IXa-specific 
aptamer) and RB007 (oligonucleotide antidote of the RB006 aptamer) [79]. RB006 is a 2′-ribo 
purine/2′-fluoro pyridimidine aptamer and is conjugated to a 40 kDa PEG to protect the aptamer 
against nuclease-mediated degradation. In addition, many aptamer-based drugs, such as AS1411   
(a nuclein-specific aptamer) for acute myeloid leukemia, ARC1779 (a vonWillebrand factor-specific 
aptamer) for carotid artery disease, and NU172 (a thrombin-specific aptamer) for anticoagulation, are 
currently in a clinical trials [80–86].  
4.3. Drug Delivery System 
Aptamers that bind to internalized cell surface receptors have been exploited to deliver drugs and  
a variety of other cargo into cells. For example, the prostate-specific membrane antigen (PSMA) is  
an important prostate cancer marker [87]. The dual aptamer probe—an A10 aptamer for PSMA(+) 
prostate cancer cells, and a DUP-1 aptamer for PSMA(−) prostate cancer cells—was invented, and a 
drug-loaded dual aptamer complex was constructed by loading doxorubicin, an anticancer drug, onto 
the A10 aptamer strand (Figure 11(a)). As a result, the doxorubicin can be effectively introduced into 
the prostate cancer cells [88].  
Small interfering RNAs (siRNAs) have received considerable attention recently as a new class of 
therapeutics for a variety of diseases. The role of siRNA is to induce an RNA interference (RNAi) 
pathway, which regulates the expression of a specific gene. In particular, it is important to efficiently 
and safely deliver siRNAs into specific cells in order for the therapeutic use of the siRNAs to be 
effective. Levy’s group introduced an siRNA-aptamer conjugate via a modular streptavidin bridge Sensors 2012, 12  
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using an anti-PSMA aptamer for prostate cancer cells (LNCaP) (Figure 11(b)) [89]. As a result, the 
conjugates could be added into the LNCaP cells within 30 min, and the siRNA-mediated inhibition of 
gene expression was observed to be effective. 
Figure 11. (a) A schematic illustration of the active targeting of the drug doxorubicin to 
prostate cancer cells using the dual-aptamer (A10 and DUP-1) complex. Doxorubicin that 
is bound to an A10 aptamer can enter both PSMA(+) and PSMA(−) prostate cancer cells 
via the dual-aptamer complex; (b) Design of an siRNA-aptamer conjugate via a modular 
streptavidin bridge using an anti-PSMA aptamer for prostate cancer cells (LNCaP). 
 
4.4. Bio-Imaging 
Another application is bio-imaging, using an aptamer that is conjugated to a fluorophore, a QD,  
or other materials such as gadolinium, which is useful for magnetic resonance imaging (MRI). Using 
aptamers as imaging agents has the advantage of their being non-toxic, because oligonucleotide moieties 
are present in the human body. Additionally, as aptamers have high specificity for their target, accurate 
targeting, and rapid diffusion through the blood circulation, use of these molecules can increase the 
certainty of the results obtained during diagnosis or clinical analysis. Based on these advantages, 
aptamers have been studied as imaging agents for cell imaging as well as single-protein imaging.  
Kim’s group published the results of C6 cell imaging using a Cy3-labeled AS1411 aptamer, which 
included a chemical modification of 5-(N-benzylcarboxyamide)-2′-deoxyuridine (called 5′-BzdU) on a 
thymidine base [90]. The AS1411 aptamer is specific for the nucleolin transmembrane protein in cancer 
cells. Specifically, this group improved the aptamer’s binding affinity to its target via a chemical 
modification. The cell imaging of the modified Cy3-labeled AS1411 aptamer was more efficient for 
the C3 cells than the original Cy3-labeled AS1411 aptamer. 
The QD-A10 and DUP-1 aptamer complex, which is specific for PSMA(+) and PSMA(−) prostate 
cancer cells (LNCaP and PC3), was shown by imaging to bind only to prostate cancer cells and not to 
normal (PNT2) or other cancer cells [91]. Additionally, an aptamer specific for p68 in liver tumors and 
an aptamer specific for small cell lung cancer (SCLC) cells were also demonstrated to have potential 
as bio-imaging probes [92–94]. Sensors 2012, 12  
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4.5. Western Blot Analysis 
A Western blot analysis is an analytical technique routinely used to quantify specific proteins 
(Figure 12(a)). The procedure includes complicated and elaborate steps and requires many reagents, 
such as two types of antibodies. There are now many reagent companies that specialize in providing 
antibodies against tens of thousands of different proteins. Hah’s group published a new aptamer-based 
Western blot strategy that has reduced the procedure to one step, and easily detects the target protein 
using only one aptamer (Figure 12(b)). Instead of two types of antibodies, the QD-conjugated RNA 
aptamer specific for the His-tag was employed. This method has the advantages of requiring less time, 
not requiring antibodies or 
32P, and introducing the possibility of multiplexing detection [95]. 
Figure 12. (a) The conventional Western blot analysis, (b) The aptamer-based Western blot analysis. 
 
4.6. Aptamer Affinity Chromatography 
Immunoaffinity purification is a general laboratory technique used in many scientific fields, that 
relies on the interaction between an antigen and an antibody to purify target proteins. The use of an 
aptamer in chromatography has many advantages over the use of an antibody, including an equal or 
superior affinity and specificity to the target, a smaller size, easier modification and immobilization, 
better stability, and higher reproducibility. Drolet’s group developed an aptamer affinity chromatography 
system for human L-selectin. The recombinant human L-selectin-Ig fusion protein was successfully 
purified from Chinese hamster ovary (CHO) cell-conditioned medium using this aptamer affinity 
column [96]. Additionally, in Le’s group, it was demonstrated that a designed sandwich aptamer 
affinity chromatography using two aptamers improved the sensitivity and selectivity for thrombin [97]. 
5. Conclusions 
In this review article, the advantages of aptamers and their applications have been presented 
through descriptions of several excellent investigation projects. An aptamer is a convincing substitute 
for an antibody because it is very stable under hot or hazardous conditions. Since aptamers are mostly 
oligonucleic acids, they can easily be synthesized in quantity with high purity, and can be modified 
with various molecules using simple chemical reactions. Therefore, aptamers have shown great 
strength in a wide range of applications. Moreover, aptamers are non-immunogenic and non-toxic 
materials that can be exploited in medical applications, such as diagnosis and treatment of diseases. It 
is also noteworthy that the types of target molecules are unlimited. Diverse SELEX methods have been Sensors 2012, 12  
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designed as the targets to select aptamers conveniently and quickly. Affinity chromatography and 
magnetic bead-based SELEX are powerful techniques for relatively large molecules such as proteins, 
because of their high affinity to the target and easy separation from dispensable molecules. Besides, 
capillary electrophoresis-based SELEX is suitable for small molecules and is a rapid method. 
Aptamers against biomarker related diseases can be used to diagnose these diseases. In the ALISA and 
RDT methods, aptamers have been used as capture-probe molecules, based on their affinity and 
selectivity to the targets. As a result, sensors have shown excellent performance in diagnosis of diseases. 
For the detection of small molecules, aptamers will be utilized pivotally, because antibody-based 
detection has considerable limitations, while the applications of aptamers are relatively broad. Numerous 
sensor techniques incorporating aptamers have been described, such as electrochemical, colorimetric, 
optical, and mass-sensitive methods. These aptasensors are being employed in various fields, including 
the medical and industrial fields. Beyond this, the use of aptamers as drugs, therapeutics, bio-imaging 
materials, and analytical reagents have been investigated and, as a result, the drug Macugen came into 
the world. In conclusion, it is certain that aptamers are a strong and versatile alternative to antibodies. 
Of course, aptamers still have issues that need to be resolved for purposes of biological applications. 
For example, if they are used as agents for in vivo applications, unmodified aptamers are highly 
susceptible to degradation by several nucleases, and their small size makes them liable to renal 
filtration, but it can be expected that the potential of aptamers for bio-applications will increase, based 
on their merits. Thus, further investigations into aptamers and aptasensor systems need to be carried 
out in order to quckly overcome existing limits. 
Acknowledgments 
This work was supported by the National Research Foundation of Korea (NRF-20100019914) and 
the National Research Foundation of Korea (NRF-20110013431). 
References 
1.  Dollins, C.M.; Nair, S.; Sullenger, B.A. Aptamers in immunotherapy. Hum. Gene. Ther. 2008, 19, 
443–450. 
2.  Sullenger, B.A.; Gallardo, H.F.; Ungers, G.E.; Gilboa, E. Overexpression of TAR sequences 
renders cells resistant to human immunodeficiency virus replication. Cell 1990, 63, 601–608. 
3.  O’Malley, R.P.; Mariano, T.M.; Siekierka, J.; Mathews, M.B. A mechanism for the control of 
protein synthesis by adenovirus VA RNAI. Cell 1986, 44, 391–400. 
4.  Burgert, H.G.; Ruzsics, Z.; Obermeier, S.; Hilgendorf, A.; Windheim, M.; Elsing, A. Subversion of 
host defense mechanisms by adenoviruses. Curr. Top. Microbiol. Immunol. 2002, 269, 273–318. 
5.  Ellington, A.D.; Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. 
Nature 1990, 346, 818–822. 
6.  Tuerk, C.; Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to 
bacteriophage T4 DNA polymerase. Science 1990, 249, 505–510. 
7.  Han, K.; Liang, Z.; Zhou, N. Design strategies for aptamer-based biosensors. Sensors 2010, 10, 
4541–4557. 
8. Bunka,  D.H.;  Stockley, P.G. Aptamers come of age—At last. Nat. Rev. Microbiol. 2006, 4, 588–596. Sensors 2012, 12  
 
 
626
9.  Mascini, M. Aptamers and their applications. Anal. Bioanal. Chem. 2008, 390, 987–988. 
10.  Birch, J.R.; Racher, A.J. Antibody production. Adv. Drug Deliv. Rev. 2006, 58, 671–685. 
11.  Ferreira, C.S.; Missailidis, S. Aptamer-based therapeutics and their potential in radiopharmaceutical 
design. Braz. Arch. Biol. Technol. 2007, 50, 63–76. 
12.  Jayasena, S.D. Aptamers: An emerging class of molecules that rival antibodies in diagnostics. 
Clin. Chem. 1999, 45, 1628–1650. 
13. Ireson, C.R.; Kelland, L.R. Discovery and development of anticancer aptamers. Mol. Cancer 
Ther. 2006, 5, 2957–2962. 
14.  Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated 
aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002, 
22, 143–152. 
15.  Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal 
neovascularization secondary to age-related macular degeneration: Phase II study results. 
Ophthalmology 2003, 110, 979–986. 
16.  Syed, M.A.; Pervaiz, S. Advances in aptamers. Oligonucleotides 2010, 20, 215–224. 
17. Pristou pil, T.I.; Kramlova, M. Microchromatographic separation of ribonucleic acids from 
proteins on nitrocellulose membranes. J. Chromatogr. 1968, 32, 769–770. 
18.  Gopinath, S.C. Methods developed for SELEX. Anal. Bioanal. Chem. 2007, 387, 171–182. 
19.  Tombelli, S.; Minunni, M.; Mascini, M. Analytical applications of aptamers. Biosens. Bioelectron. 
2005, 20, 2424–2434. 
20.  Song, K.M.; Cho, M.; Jo, H.; Min, K.; Jeon, S.H.; Kim, T.; Han, M.S.; Ku, J.K.; Ban, C. Gold 
nanoparticle-based colorimetric detection of kanamycin using a DNA aptamer. Anal. Biochem. 
2011, 415, 175–181. 
21.  Vianini, E.; Palumbo, M.; Gatto, B. In vitro selection of DNA aptamers that bind L-tyrosinamide. 
Bioorg. Med. Chem. 2001, 9, 2543–2548. 
22.  Lévesque, D.; Beaudoin, J.D.; Roy, S.; Perreault, J.P. In vitro selection and characterization of 
RNA aptamers binding thyroxine hormone. Biochem. J. 2007, 403, 129–138. 
23. Wang, C.; Yang, G.; Luo, Z.; Ding, H. In vitro selection of high-affinity DNA aptamers for 
streptavidin. Acta Biochim. Biophys. Sin. (Shanghai) 2009, 41, 335–340.  
24.  Niazi, J.H.; Lee, S.J.; Gu, M.B. Single-stranded DNA aptamers specific for antibiotics tetracyclines. 
Bioorg. Med. Chem. 2008, 16, 7245–7253.  
25. Joeng, C.B.; Niazi, J.H.; Lee, S.J.; Gu, M.B. ssDNA aptamers that recognize diclofenac and   
2-anilinophenylacetic acid. Bioorg. Med. Chem. 2009, 17, 5380–5387.  
26.  Mendonsa, S.D.; Bowser, M.T. In vitro selection of aptamers with affinity for neuropeptide Y 
using capillary electrophoresis. J. Am. Chem. Soc. 2005, 127, 9382–9383.  
27.  Mendonsa, S.D.; Bowser, M.T. In vitro selection of high-affinity DNA ligands for human IgE 
using capillary electrophoresis. Anal. Chem. 2004, 76, 5387–5392.  
28.  Hybarger, G.; Bynum, J.; Williams, R.F.; Valdes, J.J.; Chambers, J.P. A microfluidic SELEX 
prototype. Anal. Bioanal. Chem. 2006, 384, 191–198.  
29.  Lou, X.; Qian, J.; Xiao, Y.; Viel, L.; Gerdon, A.E.; Lagally, E.T.; Atzberger, P.; Tarasow, T.M.; 
Heeger, A.J.; Soh, H.T. Micromagnetic selection of aptamers in microfluidic channels. Proc. Natl. 
Acad. Sci. USA 2009, 106, 2989–2994. Sensors 2012, 12  
 
 
627
30.  Huang, C.J.; Lin, H.I.; Shiesh, S.C.; Lee, G.B. Integrated microfluidic system for rapid screening 
of CRP aptamers utilizing systematic evolution of ligands by exponential enrichment (SELEX). 
Biosens. Bioelectron. 2010, 25, 1761–1766.  
31.  Kunii, T.; Ogura, S.; Mie, M.; Kobatake, E. Selection of DNA aptamers recognizing small cell 
lung cancer using living cell-SELEX. Analyst 2011, 136, 1310–1312. 
32.  Van Simaeys, D.; Lopez-Colon, D.; Sefah, K.; Sutphen, R.; Jimenez, E.; Tan, W. Study of the 
molecular recognition of aptamers selected through ovarian cancer cell-SELEX. PLoS One 2010, 
5, doi:10.1371/journal.pone.0013770. 
33.  Daniels, D.A.; Chen, H.; Hicke, B.J.; Swiderek, K.M.; Gold, L. A tenascin-C aptamer identified 
by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment. Proc. Natl. 
Acad. Sci. USA 2003, 100, 15416–15421. 
34.  Guthold, M.; Cubicciotti, R.; Superfine, R.; Taylor, R.M. Novel methodology to detect, isolate, 
amplify and characterize single aptamer molecules with desirable target-binding properties. 
Biophys. J. 2002, 82, 797. 
35. Tsai, R.Y.; Reed, R.R. Identification of DNA recognition sequences and protein interaction 
domains of the multiple-Zn-finger protein Roaz. Mol. Cell. Biol. 1998, 18, 6447–6456. 
36. Khati, M.; Schüman, M.; Ibrahim, J.; Sattentau, Q.; Gordon, S.; James, W. Neutralization   
of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by   
gp120-binding 2′F-RNA aptamers. J. Virol. 2003, 77, 12692–12698. 
37. Misono, T.S.; Kumar, P.K. Selection of RNA aptamers against human influenza virus hemagglutinin 
using surface plasmon resonance. Anal. Biochem. 2005, 342, 312–317. 
38. Lim, Y.C.; Kouzani, A.Z.; Duan, W. Aptasensors Design Considerations. In Computational 
Intelligence and Intelligent Systems, 1st ed.; Cai, Z., Li, Z., Kang, Z., Liu, Y., Eds.; Springer: 
Berlin, Heidelberg, Germany, 2009; Volume 51, pp. 118–127. 
39. Xu, D.; Xu, D.; Yu, X.; Liu, Z.; He, W.; Ma, Z. Label-free electrochemical detection for   
aptamer-based array electrodes. Anal. Chem. 2005, 77, 5107–5113. 
40.  Numnuam, A.; Chumbimuni-Torres, K.Y.; Xiang, Y.; Bash, R.; Thavarungkul, P.; Kanatharana, P.; 
Pretsch, E.; Wang, J.; Bakker, E. Aptamer-based potentiometric measurements of proteins using 
ion-selective microelectrodes. Anal. Chem. 2008, 80, 707–712. 
41.  Wang, X.; Zhou, J.; Yun, W.; Xiao, S.; Chang, Z.; He, P.; Fang, Y. Detection of thrombin using 
electrogenerated chemiluminescence based on Ru(bpy)3
2+-doped silica nanoparticle aptasensor via 
target protein-induced strand displacement. Anal. Chim. Acta 2007, 598, 242–248. 
42.  Feng, K.; Sun, C.; Kang, Y.; Chen, J.; Jiang, J.H.; Shen, G.L.; Yu, R.Q. Label-free electrochemical 
detection of nanomolar adenosine based on target-induced aptamer displacement Electrochem. 
Commun. 2008, 10, 531–535. 
43.  Ikebukuro, K.; Kiyohara, C.; Sode, K. Novel electrochemical sensor system for protein using the 
aptamers in sandwich manner. Biosens. Bioelectron. 2005, 20, 2168–2172. 
44.  Cho, E.J.; Lee, J.W.; Ellington, A.D. Applications of aptamers as sensors. Annu. Rev. Anal. Chem. 
2009, 2, 241–264. 
45.  Rahman, M.A.; Son, J.I.; Won, M.S.; Shim, Y.B. Gold nanoparticles doped conducting polymer 
nanorod electrodes: Ferrocene catalyzed aptamer-based thrombin immunosensor. Anal. Chem. 
2009, 81, 6604–6611.  Sensors 2012, 12  
 
 
628
46.  Chandra, P.; Noh, H.B.; Won, M.S.; Shim, Y.B. Detection of daunomycin using phosphatidylserine 
and aptamer co-immobilized on Au nanoparticles deposited conducting polymer. Biosens. 
Bioelectron. 2011, 26, 4442–4449.  
47.  Li, B.; Du, Y.; Wei, H.; Dong, S. Reusable, label-free electrochemical aptasensor for sensitive 
detection of small molecules. Chem. Commun. 2007, 28, 3780–3782. 
48.  Radi, A.E.; O’Sulivan, C.K. Aptamer conformational switch as sensitive electrochemical biosensor 
for potassium ion recognition. Chem. Commun. 2006, 3432–3434. 
49.  Le Floch, F.; Ho, H.A.; Leclerc, M. Label-free electrochemical detection of protein based on a 
ferrocene-bearing cationic polythiophene and aptamer. Anal. Chem. 2006, 78, 4727–4231. 
50.  Baker, B.R.; Lai, R.Y.; Wood, M.S.; Doctor, E.H.; Heeger, A.J.; Plaxco, K.W. An electronic, 
aptamer-based small-molecule sensor for the rapid, label-free detection of cocaine in adulterated 
samples and biological fluids. J. Am. Chem. Soc. 2006, 128, 3138–3139. 
51.  Ferapontova, E.E.; Olsen, E.M.; Gothelf, K.V. An RNA aptamer-based electrochemical biosensor 
for detection of theophylline in serum. J. Am. Chem. Soc. 2008, 130, 4256–4258. 
52. Stojanovic, M.N.; de Prada, P.; Landry, D.W. Aptamer-based folding fluorescent sensor for 
cocaine. J. Am. Chem. Soc. 2001, 123, 4928–4931. 
53. Stojanovic, M.N.; de Prada, P.; Landry, D.W. Fluorescent sensors based on aptamer self-assembly. 
J. Am. Chem. Soc. 2000, 122, 11547–11548. 
54.  Nutiu, R.; Li, Y. Structure-switching signaling aptamers. J. Am. Chem. Soc. 2003, 125, 4771–4778. 
55.  Elowe, N.H.; Nutiu, R.; Allali-Hassani, A.; Cechetto, J.D.; Hughes, D.W.; Li, Y.; Brown, E.D. 
Small-molecule screening made simple for a difficult target with a signaling nucleic acid aptamer 
that reports on deaminase activity. Angew. Chem. Int. Ed. Engl. 2006, 45, 5648–5652. 
56. Chhabra, R.; Sharma, J.; Wang, H.; Zou, S.; Lin, S.; Yan, H.; Lindsay, S.; Liu, Y.   
Distance-dependent interactions between gold nanoparticles and fluorescent molecules with DNA 
as tunable spacers. Nanotechnology 2009, 20, doi: 10.1088/0957-4484/20/48/485201. 
57. Habenicht, B.F.; Prezhdo, O.V. Nonradiative quenching of fluorescence in a semiconducting 
carbon nanotube: A time-domain ab initio study. Phys. Rev. Lett. 2008, 100, 197402:1–197402:4. 
58.  Huang, Y.; Zhao, S.; Liang, H.; Chen, Z.F.; Liu, Y.M. Multiplex detection of endonucleases by 
using a multicolor gold nanobeacon. Chemistry 2011, 17, 7313–7319. 
59.   Liu, M.; Zhao, H.; Chen, S.; Yu, H.; Zhang, Y.; Quan, X. A “turn-on” fluorescent copper biosensor 
based on DNA cleavage-dependent graphene-quenched DNAzyme. Biosens. Bioelectron. 2011, 26, 
4111–4116. 
60.  Luo, Y.; Liao, F.; Lu, W.; Chang, G.; Sun, X. Coordination polymer nanobelts for nucleic acid 
detection. Nanotechnology 2011, 22, doi: 10.1088/0957-4484/22/19/195502. 
61. Olek, M.; Büsqen, T.; Hilgendorff, M.; Giersiq, M. Quantum dot modified multiwall carbon 
nanotubes. J. Phys. Chem. B. 2006, 110, 12901–12904. 
62.  Chang, H.; Tang, L.; Wang, Y.; Jiang, J.; Li, J. Graphene fluorescence resonance energy transfer 
aptasensor for the thrombin detection. Anal. Chem. 2010, 82, 2341–2346. 
63.  Zhao, W.; Chiuman, W.; Brook, M.A.; Li, Y. Simple and rapid colorimetric biosensors based on 
DNA aptamer and noncrosslinking gold nanoparticle aggregation. ChemBioChem  2007,  8,  
727–731. Sensors 2012, 12  
 
 
629
64.  Liu, J.; Lu, Y. Fast colorimetric sensing of adenosine and cocaine based on a general sensor design 
involving aptamers and nanoparticles. Angew. Chem. Int. Ed. Engl. 2006, 45, 90–94. 
65. Liu, J.; Lu, Y. Antibody-based sensors for heavy metal ions. Biosens. Bioelectron.  2001,  16,  
799–809. 
66.  Luzi, E.; Minunni, M.; Tombelli, S.; Mascini, M. New trends in affinity sensing: Aptamers for 
ligand binding. Trends Anal. Chem. 2003, 22, 810–818. 
67.  Tombelli, S.; Minunni, M.; Luzi, E.; Mascini, M. Aptamer-based biosensors for the detection of 
HIV-1 Tat protein. Bioelectrochemistry 2005, 67, 135–141. 
68. Schlensog, M.D.; Gronewold, T.M.A.; Tewes, M.; Famulok, M.; Quandt, E. A love-wave biosensor 
using nucleic acids as ligands. Sens. Actuat. 2004, 101, 308–315. 
69.  Hianik, T.; Ostatna, V.; Zajacova, Z.; Stoikova, E.; Evtugyn, G. Detection of aptamer-protein 
interactions using QCM and electrochemical indicator methods. Bioorg. Med. Chem. Lett. 2005, 
15, 291–295. 
70. Bini, A.; Minunni, M.; Tombelli, S.; Centi, S.; Mascini, M. Analytical performances of   
aptamer-based sensing for thrombin detection. Anal. Chem. 2007, 79, 3016–3019. 
71.  Savran, C.A.; Knudsen, S.M.; Ellington, A.D.; Manalis, S.R. Micromechanical detection of proteins 
using aptamer-based receptor molecules. Anal. Chem. 2004, 76, 3194–3198. 
72. Hwang, K.S.; Lee, S.M.; Eom, K.; Lee, J.H.; Lee, Y.S.; Park, J.H. Yoon, D.S.; Kim, T.S. 
Nanomechanical microcantilever operated in vibration modes with use of RNA aptamer as receptor 
molecules for label-free detection of HCV helicase. Biosens. Bioelectron. 2007, 23, 459–465. 
73.  Cella, L.N.; Sanchez, P.; Zhong, W.; Myung, N.V.; Chen, W.; Mulchandani, A. Nano aptasensor 
for protective antigen toxin of anthrax. Anal. Chem. 2010, 82, 2042–2047. 
74.  Wang, L.; Zhu, C.; Han, L.; Jin, L.; Zhou, M.; Dong, S. Label-free, regenerative and sensitive 
surface plasmon resonance and electrochemical aptasensors based on graphene. Chem. Commun. 
2011, 47, 7794–7796. 
75.  Song, S.; Wang, L.; Li, J.; Zhao, J.; Fan, C. Aptamer-based biosensors. Trends Anal. Chem. 2008, 
27, 108–117. 
76.  Vivekananda, J.; Kiel, J.L. Anti-francisella tularensis DNA aptamers detect tularemia antigen 
from different subspecies by aptamer-linked immobilized sorbent assay. Lab. Invest. 2006, 86, 
610–618. 
77. Xu, H.; Mao, X.; Zeng, Q.; Wang, S.; Kawde, A.N.; Liu, G. Aptamer-functionalized gold 
nanoparticles as probes in a dry-reagent strip biosensor for protein analysis. Anal. Chem. 2009, 
81, 669–675. 
78. Lee, J.H.; Jucker, F.; Pardi, A. Imino proton exchange rates imply an induced-fit binding 
mechanism for the VEGF165-targeting aptamer, Macugen. FEBS Lett. 2008, 582, 1835–1839. 
79.  Becker, R.C.; Chan, M.Y. REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its 
oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis. 
Curr. Opin. Mol. Ther. 2009, 11, 707–715. 
80.  Bates, P.J.; Laber, D.A.; Miller, D.M.; Thomas, S.D.; Trent, J.O. Discovery and development of 
the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol. 2009, 86, 
151–164. Sensors 2012, 12  
 
 
630
81.  Bates, P.J.; Kahlon, J.B.; Thomas, S.D.; Trent, J.O.; Miller, D.M. Antiproliferative activity of  
G-rich oligonucleotides correlates with protein binding. J. Biol. Chem. 1999, 274, 26369–26377. 
82.  Teng, Y.; Girvan, A.C.; Casson, L.K.; Pierce, W.M., Jr.; Qian, M.; Thomas, S.D.; Bates, P.J. 
AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and 
nucleolin. Cancer Res. 2007, 67, 10491–10500. 
83.  Krieg, A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 2006, 
5, 471–484. 
84.  Krieg, A.M. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008, 27, 
161–167. 
85.  Sheehan, J.P.; Lan, H.C. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. 
Blood 1998, 92, 1617–1625. 
86.  Keefe, A.D.; Pai, S.; Ellington, A. Aptamers as therapeutics. Nat. Rev. Drug. Discov. 2010, 9, 
537–550. 
87. Lupold, S.E.; Hicke, B.J.; Lin, Y.; Coffey, D.S. Identification and characterization of   
nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific 
membrane antigen. Cancer Res. 2002, 62, 4029–4033. 
88.  Min, K.; Jo, H.; Song, K.M.; Cho, M.; Chun, Y.S.; Jon, S.; Kim, W.J.; Ban, C. Dual-aptamer-based 
delivery vehicle of doxorubicin to both PSMA (+) and PSMA (−) prostate cancers. Biomaterial 
2011, 32, 2124–2132. 
89.  Chu, T.C.; Twu, K.Y.; Ellington, A.D.; Levy, M. Aptamer mediated siRNA delivery. Nucleic 
Acids Res. 2006, 34, doi:10.1093/nar/gkl388. 
90. Lee, K.Y.; Kang, H.; Ryu, S.H.; Lee, D.S.; Lee, J.H.; Kim, S. Bioimaging of nucleolin   
aptamer-containing 5-(N-benzylcarboxyamide)-2′-deoxyuridine more capable of specific binding 
to targets in cancer cells. J. Biomed. Biotechnol. 2010, 2010, doi: 10.1155/2010/168306. 
91. Min, K.; Song, K.M.; Cho, M.; Chun, Y.S.; Shim, Y.B.; Ku, J.K.; Ban, C. Simultaneous 
electrochemical detection of both PSMA (+) and PSMA (−) prostate cancer cells using an 
RNA/peptide dual-aptamer probe. Chem. Commun. 2010, 46, 5566–5568. 
92.  Bagalkot, V.; Zhang, L.; Levy-Nissenbaum, E.; Jon, S.; Kantoff, P.W.; Langer, R.; Farokhzad, O.C. 
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug 
delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 2007, 7, 3065–3070. 
93.  Kunii, T.; Ogura, S.; Mie, M.; Kobatake, E. Selection of DNA aptamers recognizing small cell 
lung cancer using living cell-SELEX. Analyst 2011, 136, 1310–1312. 
94.  Mi, J.; Liu, Y.M.; Rabbani, Z.N.; Yang, Z.G.; Urban, J.H.; Sullenger, B.A.; Clary, B.M. In vivo 
selection of tumor-targeting RNA motifs. Nat. Chem. Biol. 2010, 6, 22–24. 
95.  Shin, S.; Kim, I.; Kang, W.; Yang, J.K.; Hah, S.S. An alternative to Western blot analysis using 
RNA aptamer-functionalized quantum dots. Bioorg. Med. Chem. Lett. 2010, 20, 3322–3325. 
96.  Romig, T.S.; Bell, C.; Drolet, D.W. Aptamer affinity chromatography: Combinatorial chemistry 
applied to protein purification. J. Chromatogr. B 1999, 731, 275–284. 
97.  Zhao, Q.; Li, X.F.; Shao, Y.; Le, X.C. Aptamer-based affinity chromatographic assays for thrombin. 
Anal. Chem. 2008, 80, 7586–7593. 
  Sensors 2012, 12  
 
 
631
Appendix 
Table A1. Aptamer-based sensor. 
 Method  Material  Reference 
Electrochemical 
aptasensor 
Electrochemical impedance 
spectroscopy (EIS) 
Label-free [39] 
Fe(CN)6
4−/3− [45] 
Ferrocene [46] 
Potentiometry-based  
ion-selective  
electrodes (ISEs) 
CdS quantum dot (QD)  [40] 
Electrogenerated 
chemiluminescence (ECL) 
Ru(bpy)3
2+ [41] 
Cyclic voltammetry (CV) 
MB [42] 
Pyrroquinoline quinone (PQQ)  [43] 
Ferrocene [49] 
Gold nanorod (AuNRs)-modified 
conducting polymer 
[47] 
Differential pulse 
voltammetry (DPV) 
Ferrocene [51] 
AuNRs-modified conducting polymer  [48] 
Optical 
aptasensor 
Fluorescence quenching/ 
fluorescence resonance 
energy transfer (FRET) 
Fluorophore/dabcyl moieties  [52] 
Fluorophore/gold nanoparticle 
(AuNP) 
[56,58] 
Fluorophore/carbon nanotube (CNT)  [57] 
Fluorophore/graphene [59,62] 
Fluorophore/polymer [60] 
QD/CNT [61] 
AuNP-based colorimetry  AuNPs  [63,64] 
Other 
aptasensor 
Quartz crystal 
microbalance  
(QCM)-based 
 [67,70] 
Microcantilever-based  [71,72] 
SPR-based   [74] 
Table A2. Aptamer-based new drugs. 
New drug  Type  Target-specific aptamer  Reference
Macugen  Treatment for AMD  VEGF-specific aptamer  [78] 
REG1 Anti-blood  clotting  Coagulation factor lxa-specific aptamer  [79] 
AS1411 Anti-cancer  agent  Nucleolin-specific aptamer [80–82] 
APG7909 
Anti-cancer agent  TLR 9-specific aptamer  [83,84] 
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